







C O R R E S P O N D E N C E
Reply to von Reyn and Horsburgh
To the Editor—We thank von Reyn 
et  al [1] for their interest in our work 
and for providing pertinent data on the 
impact of nontuberculous mycobacteria 
(NTM) infection on the screening for 
latent tuberculosis infection, which sup-
port the results of our trial. We whole-
heartedly agree with their conclusion on 
the value of using an interferon γ release 
test when screening for tuberculosis 
infection regardless of the presence of 
BCG vaccination.
In an ad hoc analysis of our data 
set, 28% of the non–BCG-immunized 
contacts with a positive tuberculin 
skin test (TST) result had a negative 
QuantiFERON-TB Gold In-Tube (QFT-
GIT) test result, (18% for contacts with 
a TST reaction >15  mm, 23% for those 
with a reaction 11–15 mm, and 78% for 
those with a reaction 5–10  mm). Even 
considering that the TST result may have 
been positive in a substantial proportion 
of these contacts because of sensitization 
with NTM, our figures are below those 
obtained among healthcare workers in 
United States, probably owing first to 
the higher risk of tuberculosis infection 
among our contacts and second to the 
lower prevalence of NTM in our coun-
try. According to unpublished data, the 
prevalence rate of respiratory isolation of 
NTM in our region is 8 per 100 000 pop-
ulation, which is clearly lower than the 
US rates [2].
Together with the valuable data pro-
vided by von Reyn et  al, our results 
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strongly suggest that applying our strat-
egy of using the QFT-GIT test in the 
tuberculosis household contact inves-
tigation in areas with high prevalence 
of NTM would reduce the number of 
preventive treatments even further. 
However, it should be kept in mind 
that the safety of this strategy has been 
proved only for screening immunocom-
petent persons with the QFT-GIT test, 
and presumably with the new-genera-
tion QuantiFERON-TB Gold Plus test.
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C-Reactive Protein Response in 
Patients With Post-Treatment 
Lyme Disease Symptoms 
Versus Those With Myalgic 
Encephalomyelitis/Chronic 
Fatigue Syndrome
To the Editor—There is substantial 
overlap in symptoms, including fatigue, 
muscle and joint pain, and cognitive and 
memory deficits, between post-treatment 
Lyme disease syndrome (PTLDS) and 
myalgic encephalomyelitis/chronic fatigue 
syndrome (ME/CFS) [1]. Increasing evi-
dence suggests a role for immunologic 
and inflammatory pathways in both 
PTLDS and ME/CFS [2–4]. However, in 
part owing to their etiologic complexity 
and the lack of established biomarkers, our 
understanding of the pathways involved 
and potential mechanistic differences 
between the 2 conditions is very limited.
In a 2016 study published in Clinical 
Infectious Diseases, Uhde et al [5] exam-
ined the concentrations of acute-phase 
response proteins, including C-reactive 
protein (CRP), in individuals with 
PTLDS. CRP is a highly sensitive marker 
of infection and inflammation that binds 
a variety of ligands present on the sur-
face of pathogens or exposed during 
autologous cell stress or death, exerting 
its effect through opsonin deposition 
and activation of the complement path-
way, in addition to direct interaction 
with phagocytic cells [6]. We found that 
the circulating levels of CRP, as well as 
the frequency of concentrations >3  mg/
mL (generally considered to represent 
some degree of inflammation [7]) to be 
significantly higher in the PTLDS cohort 
than in a control group of subjects who 
had a history of Lyme disease but with-
out persistent symptoms (both P < .001). 
The data provided evidence for increased 
expression of an objective marker of 
inflammation in PTLDS but suggested 
a mechanism of activation distinct from 
that in active infection, as previously dis-
cussed [5].
Using the same methods [5] in a new 
study, we screened plasma samples from 
131 patients with ME/CFS (89 female; 
mean age [standard deviation], 50.0 
[11.4] years; mean body mass index 
(BMI), 26.0 [5.5]) and 86 healthy con-
trols (68 female; mean age, 50.0 [12.8] 
years; mean BMI, 26.5 [6.8]), provided 
by the SolveCFS BioBank [8]. Patients 
with ME/CFS met the criteria of Fukuda 
et al [9] and the Canadian criteria [10] 
for this condition [9, 10]. Screening 
questionnaires were used to evaluate 
the general health of the unaffected con-
trols and to confirm that they did not 
meet ME/CFS case definition criteria. 
The ME/CFS and control sample sizes 
provided >95% power, with an α  value 
<.05, to detect the same increase in CRP 
response as in the patients with PTLDS 
[5]. Group differences were assessed 
by the analysis of covariance, using the 
general linear model, to account for the 
potential confounding effect of age, sex, 
and BMI. This study was approved by the 
Institutional Review Board of Columbia 
University. In contrast to data from 
patients with PTLDS [5], we did not find 
a statistically significant difference in 
the circulating levels of CRP (Figure 1) 
or the frequency of CRP levels >3 mg/L 
(33 of 131 [25.2%] vs 22 of 86 [25.6%], 
respectively) between patients with ME/
CFS and controls.
These data provide evidence for the 
likely existence of distinct inflammatory 
mechanisms in ME/CFS versus PTLDS, 
which may be driven in part by the poten-
tially more heterogeneous etiology of 
ME/CFS symptoms in comparison with 
PTLDS. The absence of a significantly 
enhanced CRP response in ME/CFS, des-
pite published data suggesting activation 













Figure  1. C-reactive protein (CRP) concentrations 
in the cohorts of patients with myalgic encephalomy-
elitis/chronic fatigue syndrome (ME/CFS) and healthy 
controls (HCs). The difference between the 2 groups 
was not statistically significant (P = .55). Horizontal red 
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